Two Sigma Advisers
BCLI

Two Sigma Advisers’s BRAINSTORM CELL THERAPUTC BCLI Stock Holding History

Two Sigma Advisers’s Portfolio BCLI Stock Details BCLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-733
Closed -$37K – 2660
2022
Q1 		$37K Sell
733
-40
-5% -$1.96K ﹤0.01% 2619
2021
Q4 		$46K Buy
773
+60
+8% +$2.95K ﹤0.01% 2479
2021
Q3 		$35K Sell
713
-600
-46% -$31.6K ﹤0.01% 2390
2021
Q2 		$75K Sell
1,313
-6,714
-84% -$359K ﹤0.01% 2364
2021
Q1 		$461K Buy
+8,027
New +$606K ﹤0.01% 2048

Other funds holding BCLI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AHB
Abner Herrman & Brock Jersey City, New Jersey $1.05B AUM 42.66% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
RJA
Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
WCG
Weaver Consulting Group Huntington Beach, California $420M AUM 14.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Two Sigma Advisers's BCLI Position: Q2 2022 in Review

Two Sigma Advisers sold out of BRAINSTORM CELL THERAPUTC (BCLI) in Q2 2022, closing a stake of 733 shares — an estimated $37K sold.

Two Sigma Advisers first reported a position in BCLI in Q1 2021 and held it in 5 quarters. The position peaked at $461K in Q1 2021. 48 funds tracked by Wall St. Rank hold BCLI as of Q2 2022.

  • Two Sigma Advisers reported no remaining BRAINSTORM CELL THERAPUTC position as of Q2 2022 after selling out during the quarter.
  • Two Sigma Advisers sold 733 BRAINSTORM CELL THERAPUTC shares in Q2 2022, an estimated $37K.
  • Two Sigma Advisers first reported a position in BRAINSTORM CELL THERAPUTC in Q1 2021 and held it in 5 quarters.
  • Two Sigma Advisers's BRAINSTORM CELL THERAPUTC position peaked at $461K in Q1 2021.
  • 48 funds tracked by Wall St. Rank held BRAINSTORM CELL THERAPUTC as of Q2 2022.

Based on Two Sigma Advisers's 13F filing for Q2 2022, filed 15 Aug 2022.